|MP 7.01.84||Semi-Implantable and Fully Implantable Middle Ear Hearing Aids|
|Original Policy Date
|Last Review Status/Date
Reviewed with literature search/4:2013
|Return to Medical Policy Index|
Our medical policies are designed for informational purposes only and are not an authorization, or an explanation of benefits, or a contract. Receipt of benefits is subject to satisfaction of all terms and conditions of the coverage. Medical technology is constantly changing, and we reserve the right to review and update our policies periodically.
Patients with hearing loss are typically fitted with external acoustic hearing aids. Semi-implantable and fully implantable middle ear hearing aids have been developed as an alternative to external acoustic hearing aids.
Hearing loss is described as conductive, sensorineural, or mixed, and can be unilateral or bilateral. Normal hearing is the detection of sound at or below 20 decibels (dB). The American Speech Language- Hearing Association (ASLHA) has defined the degree of hearing loss based on pure-tone average (PTA) detection thresholds as mild (20 to 40 dB), moderate (40 to 60 dB), severe (60 to 80 dB), and profound (greater or equal to 80 dB).
Sound amplification through the use of an air-conduction (AC) hearing aid can provide benefit to patients with sensorineural, conductive, or mixed hearing loss. Contralateral routing of signal (CROS) is a system in which a microphone on the affected side transmits a signal to an air-conduction hearing aid on the normal or less affected side.
Patients with moderate to severe sensorineural hearing loss are typically fitted with external acoustic hearing aids. However, these hearing aids may not be acceptable to patients, either due to issues related to anatomic fit, sound quality, or personal preference. Conductive hearing loss may be treated with acoustic or bone conduction hearing aids when surgical or medical interventions are unable to correct hearing loss. Semi-implantable and fully implantable middle ear hearing aids have been developed as an alternative to external acoustic hearing aids.
Two semi-implantable devices received approval by the U.S. Food and Drug Administration (FDA), the Vibrant® Soundbridge™, approved in August 2000, and the Soundtec® Direct System™, approved in September 2001. The Soundtec was subsequently discontinued by the manufacturer. The FDA labeling approved for both devices states that they are “… intended for use in adults, 18 years of age or older, who have a moderate to severe sensorineural hearing loss and desire an alternative to an acoustic hearing aid." The devices consist of 3 components: a magnetic component that is implanted onto the ossicles of the middle ear, a receiver, and a sound processor. The Soundbridge device is implanted subcutaneously behind the ear while the processor is worn externally on the scalp over the receiver unit and held in place by a magnet. The Soundtec device was placed in the user’s ear canal while the processor would rest over the external ear. In general, the sound processor receives and amplifies the sound vibrations and transforms the sound pressure into electrical signals that are received by the receiver unit. The receiver unit then transduces these electrical signals into electromagnetic energy and creates an alternating electromagnetic field with the magnetic component (floating mass transducer) implanted on the ossicles of the middle ear. This electromagnetic field results in attractive and repulsive forces on the magnetic implant, causing vibration of the bones of the middle ear similar to normal hearing.
The Esteem® Implantable Hearing System by Envoy Medical Corporation is a fully implantable middle ear hearing aid that received FDA approval in March 2010. The FDA-approved labeling for the Esteem hearing implant indicates it is “intended to alleviate hearing loss...in adults 18 years of age or older with stable bilateral sensorineural hearing loss.” This device uses piezoelectric transduction as opposed to the electromagnetic transduction used in the semi-implantable devices. A piezoelectric transducer, the sensor, is placed at the head of the incus and converts mechanical vibrations detected from the tympanic membrane to electrical signals that are delivered to the stapes by another piezoelectric transducer, the driver.
Semi-implantable and fully implantable middle ear hearing aids are considered investigational.
For reference, the package insert of the Vibrant Soundbridge device describes the following patient selection criteria:
- Pure-tone air-conduction threshold levels shall fall at or within:
- Word recognition score of 50% or better, using recorded material
- Normal middle ear anatomy
- Psychologically and motivationally suitable with realistic expectations of the benefits and limitations of the device.
The Esteem device is indicated for patients with hearing loss meeting the following criteria:
- 18 year of age or older
- Stable bilateral sensorineural hearing loss
- Moderate (hearing loss between 40 and 70 dB) to severe (hearing loss between 71 and 90 dB) sensorineural hearing loss defined by Pure Tone Average (PTA)
- Unaided speech discrimination test score greater than or equal to 40%
- Normally functioning eustachian tube
- Normal middle ear anatomy
- Normal tympanic membrane
- Adequate space for Esteem implant determined via high resolution CT [computed tomography] scan
- Minimum 30 days of experience with appropriately fit hearing aids.
BlueCard/National Account Issues
Benefit/contractual restrictions or exclusions for acoustic hearing aids for moderate to severe sensorineural hearing loss may apply.
State or federal mandates (e.g., FEP) may dictate that all FDA-approved devices may not be considered investigational, and thus these devices may be assessed only on the basis of their medical necessity.
The issue of upgrading components of middle ear implants may be best addressed contractually.
Some facilities may negotiate a global fee for the implantation of the device and the associated aural rehabilitation. However, charges for rehabilitation may be subject to individual contractual limitations.
This policy was created in 2002 and updated regularly with searches of the MEDLINE database. The most recent literature search was performed through February 11, 2013.
Externally worn acoustic hearing aids are widely accepted devices for patients with hearing loss. Therefore this policy of semi-implantable and fully implantable hearing aids will focus on various audiologic measures achieved with an externally worn hearing aid compared to a semi- or fully implantable hearing aid in the same patient. Another outcome that has been studied is patient preference for an implantable device compared to an externally worn device. However, it must be determined to what extent patient preference is based on convenience, which is not an element of medical necessity, compared to preference based on improved hearing. Only minimal safety concerns are related to external hearing aids. In contrast, an implantable hearing aid requires a surgical procedure for implantation. Potential risks cited for semi-implantable middle ear hearing aids include decrease in residual hearing in the implanted ear, infection in the ear and adjacent structures, and general anesthesia. Major ear surgery may also result in numbness, swelling, or discomfort around the ear, the possibility of facial paresis, neck pain, and disturbance of balance and taste. Therefore, equivalency or improvement in audiologic outcomes associated with an implantable hearing aid must be balanced against the potential risks inherent in a surgical procedure.
Semi-Implantable Hearing Aids
Clinical trials for U.S Food and Drug Administration (FDA) Approval of Semi-Implantable Middle Ear Hearing Aids
FDA approval of the Soundbridge and Soundtec devices was based in part on clinical trials of 53 and 108 respective patients who had moderate to severe sensorineural hearing loss and who were dissatisfied with their existing external acoustic hearing aid. Results of these trials are available in the FDA Summaries of Safety and Effectiveness. (1, 2) The results of the Soundbridge and Soundtec trials have also been reported in the peer-reviewed published literature. (3) The principal outcome measures were the audiologic outcomes before (with the hearing aid in use) and after the implant. The following audiologic outcomes were reported:
Functional gain is defined as the difference in sound field threshold (measured in decibels, dBs) and is an indicator of functional benefit from an amplification device. For the Soundbridge device, the improvement in functional gain was 14.1 dB, while for the Soundtec device, it was 7.9 dB; both are considered a modest improvement. The clinical significance of this improvement is difficult to determine. For example, this level of improvement may be more clinically significant in patients with moderate hearing loss, for whom a 14-dB improvement in threshold might move them into the normal range for the spoken voice.
Speech recognition is assessed using Speech Perception in Noise (SPIN) test and the Northwestern University-6 test (NU-6), which consists of a 50-item word list. For the Soundbridge device, no significant difference in word recognition was found in quiet or noisy conditions between the implant and acoustic hearing aid. For the Soundtec device, a statistically significant improvement was noted in results of the NU-6 and SPIN test at 52 weeks compared to an optimally fitted hearing aid. However, only 12 patients had completed the 52-week follow-up.
Patient self-evaluation was performed in a variety of ways. The Profile of Hearing Aid Performance (PHAP) consists of 7 subscales that measure several dimensions of hearing aid effectiveness, such as ease of communications, reverberation, distortion of sound, etc. The Hearing Device Satisfaction Scale (HDSS) was developed by Symphonix, the manufacturer. This scale evaluated hearing aid and Soundbridge use and the general satisfaction level. The number of subjects who reported improvement was significant across all 7 subscales of the PHAP. The largest improvements in the Soundbridge compared to the acoustic hearing aid were reported for reverberation, reduced cues, and background noise. Based on the HDSS, 94% reported improved overall sound quality for the Soundbridge. For the Soundtec device, patient satisfaction was based on the Hough Ear Institute Profile. This profile assesses patient preference, acoustic feedback, perception of speech quality, occlusion, and tinnitus. At 20 weeks post-implant, improvements in all of the parameters were clinically significant. For example, 89% of patients preferred the implantable hearing aid to the acoustic hearing aid, although this result is not surprising since only patients who were dissatisfied with their previous acoustic hearing participated in the trial. A total of 67% of patients reported feedback with their previous acoustic hearing aid, while only 9% reported feedback with the implanted device. The clinical significance of the improvement in functional gain and speech perception is uncertain, although there appears to be a clear patient preference for the implantable devices.(4)
Minimal safety issues appeared associated with either device. In the Soundbridge device, the most common complication was a fullness sensation in 18, which did not resolve in 13. Altered taste sensation was reported in 7 and transient pain in 13. Two patients reported a reduction in residual hearing. In the Soundtec device, the most common complication included device noise, ear pain, ear irritation, and processor failure. These complications resolved in almost all patients; no patient requested removal of the device. However, risks can only be adequately evaluated in broader populations over time.
Additional Studies for Semi-Implantable Middle Ear Hearing Aids
A systematic review by Tysome and colleagues, in 2010, examined 17 studies (out of 644 articles identified) comparing hearing improvements in middle-ear hearing implants to conventional hearing aids. (5) The authors noted high-quality, long-term studies are not available. However, they concluded there was sufficient evidence to support the use of middle ear hearing aid implants. They noted hearing gains with middle ear hearing aid implants were comparable to gains with conventional hearing aids and may even improve sound quality and speech perception. Furthermore, they noted the evidence did not demonstrate a decrease in residual hearing.
Results of a 2002 Phase II trial of the SoundTec system were published, (6) but this publication lags behind the data included in the FDA summary of safety and effectiveness. (2) An additional case series of 64 SoundTec implants was published in 2005. (7) The average functional gain varied with frequency, with the lowest functional gain in the lower speech frequencies (7.9 dB), with increasing functional gain at higher frequencies, ranging up to 27 dB at the highest frequency of 6,000 Hz. The functional gain of 7.9 dB at the speech frequencies is similar to that reported in the FDA summary of safety and effectiveness, while it is markedly higher in the higher frequencies. The cause of this marked discrepancy is not apparent. In this case series, the authors also reported that a high percentage of patients were hearing the magnet move inside the ear, resulting in a refinement of the surgical procedure to better stabilize the magnet.
Truy and colleagues reported on the Vibrant Soundbridge versus conventional hearing aids in 6 patients with sensorineural high-frequency hearing loss and found some improvements in hearing with the Soundbridge system. (8) Additional small studies report early results of coupling the Vibrant Soundbridge system to the cochlea round window for patients with mixed hearing loss (9, 10) and for conductive and mixed hearing loss, (11) sloping high-frequency sensorineural hearing loss, (12) and aural atresia. (13-15) However, these studies are small (ranging from 5 to 25 patients) and should be considered preliminary. Additionally, the Vibrant Soundbridge is not approved by the FDA for use in conductive and mixed hearing loss.
Studies from European centers reported early results of combining the Soundbridge system with stapes surgery for otosclerosis. For example, in 2007, Venail et al. report on results of using this combined approach in 4 patients. (16) These results should be considered preliminary. In addition, in the United States, this use would not be consistent with the FDA-approved labeling.
Zwartenkot et al. reported on a transcanal approach to implantation of the Vibrant Soundbridge in 13 adults with chronic external otitis and sensorineural hearing loss. (17) The authors reported the transcanal approach resulted in several postoperative complications over 51 months of follow-up including extrusion of the conducting wire into the ear canal in 5 cases. After repair of the wire extrusions, 3 cases experienced repeated extrusion. Therefore, the transcanal approach is not recommended for Soundbridge system implantation in patients with external otitis.
Fully Implantable Hearing Aid
Clinical trials for FDA Approval of a Fully-Implantable Middle Ear Hearing Aid
The U.S. Food and Drug Administration (FDA) approval of the Esteem device was based on a prospective, nonrandomized, multicenter clinical trial of 60 patients with moderate-to-severe sensorineural hearing loss designed to assess the safety and efficacy of the Esteem Hearing System. (18) Patients served as both control and test subject as hearing was tested before (with and without hearing assistive devices) and after Esteem implantation. Results of this trial are available in the FDA Summaries of Safety and Effectiveness. In this study, patients experienced an improvement of 11.4 dB in mean speech reception threshold at 10 months’ post-implantation when compared to pre-implant aided speech reception thresholds. Overall, word recognition scores were equal to or better than pre-implant aided scores in 93% of patients. The other 7% experienced lower word recognition scores than pre-implant scores using hearing aids.
Ninety-six adverse device events occurred and were considered to be not serious. Taste disturbance was reported to be the most common side effect reported at 42% followed by tinnitus in 18% and facial paralysis/paresis in 7% of patients. Severe adverse device effects were experienced in 6 of the 57 patients implanted and included 3 revisions due to fibrous adhesions which limited implant benefit, 1 incision breakdown which required explantation, and 1 wound infection and 1 severe pain and facial weakness case, both of which resolved when treated with medication. Overall, 70% of all adverse events resolved at 10-month follow-up. However, the serious adverse event of facial paralysis/palsy had not resolved in 2 patients.
Kraus and colleagues reported on 1-year follow-up of the Esteem study in 2011. (19) Results were similar to those reported to the FDA at 10 months’ follow-up. Speech reception thresholds improved 11.8 dB + 1.8 dB from a mean pre-implant aided score of 41.2 dB to 29.4 dB (p<0.001). Word recognition scores improved by a mean of 19.8 % + 4.3 from pre-implant aided scores. The authors reported 133 adverse events including 3 cases of facial paresis resolved with medication.
Additional Studies for a Fully-Implantable Middle Ear Hearing Aid
Reports in the literature on use of a totally implantable hearing device are few. Barbara and colleagues reported on use of the 2010 FDA-approved totally implantable Esteem device in 21 patients with severe bilateral sensorineural hearing loss. (20) The authors reported mean hearing threshold levels improved overall from 70 to 48 dB. In another article reporting on 6 patients implanted with the Esteem device, Barbara et al. found the device improved hearing when assessed during postoperative fittings. (21) Chen and colleagues reported on the Phase I results of the Envoy Totally Implantable Hearing System in 7 patients followed up at 2 and 4 months after activation of the device. (22) Improvements in word recognition and communication in background noise over best-fit hearing aid usage was perceived in 5 patients. Patient outcomes in functional gain and speech reception thresholds were comparable to best-fit hearing aid usage.
Several recent small case series (23-26) provide insufficient evidence to alter the conclusions of the current policy (see the Literature Review for this Policy update). A systematic review of literature on the Esteem device included 7 articles that met inclusion criteria. (27) Complication rates with the Esteem device most commonly included taste disturbance. Clinically significant improvements in functional gain, speech reception, and speech recognition over the unaided condition were reported. In studies comparing the Esteem implant to conventional hearing aids, findings were mixed. Improvements in functional gain were similar to those for hearing aids; however, speech recognition and quality of life were greater with the implants. This limited evidence suggests these devices may offer a relatively safe and effective treatment option, particularly for patients who are medically unable to wear conventional hearing aids. However, the included studies were primarily quasi-experimental, pre/post comparisons of aided and unaided conditions. Furthermore, because of heterogeneity across studies, meta-analysis was not performed, and comparisons were made by structured review.
The publications cited herein report on short-term results from a small number of patients and overall, demonstrate insufficient evidence to support the medical necessity of available fully implantable hearing aid device(s).
Ongoing Clinical Trials
Only one active study on middle ear hearing aids was identified at online site ClinicalTrials.gov. The Envoy Medical Corporation continues to study the Esteem Totally Implantable Hearing System in the 57 patients from the premarket approval (PMA) clinical trial reported to the FDA. The study will further evaluate the long-term (5 years) hearing outcomes of speech reception threshold and word recognition score along with adverse events (NCT01092910). This trial is expected to be completed in 2015. Per agreement with the FDA, Envoy will also conduct a new prospective, multi-center, non-randomized, audiologist-blinded, 1-arm observational study of 120 patients. This study, which has not yet begun, will address safety at 1 month by evaluating the incidence of facial pareses/paralyses and effectiveness at 5 years by evaluating speech reception threshold and word recognition score.
The limited data suggest semi-implantable middle ear hearing aids may provide marginal improvement in hearing compared to conventional external acoustic hearing aids in patients with sensorineural hearing loss. However, given the safety and effectiveness of external acoustic hearing aids and the increased risks inherent in a surgical procedure, the semi-implantable device must be associated with clinically significant improvement in various hearing parameters compared to external hearing aids. While safety concerns appear to be minimal, only a limited number of patients have been included in the clinical trials, and few have completed more than 1 year of follow-up. Given the small number of patients and the limited safety data, risks cannot be adequately evaluated and compared with the marginal improvement in hearing. Studies on patients with conductive or mixed hearing loss and aural atresia, when external acoustic hearing aids are not an option, have also demonstrated hearing benefit with semi-implantable middle ear hearing aids. However, these studies are few and limited to small numbers of patients. Therefore, conclusions on the safety and effectiveness of semi-implantable hearing aids in these patients cannot be made, and further study with longer term follow-up is needed. Comparisons of semi-implantable devices with alternative hearing devices such as implantable bone-conduction and bone-anchored hearing aids would also be useful to determine device appropriateness for patients who are unable to use external air-conduction hearing aids. Due to the lack of adequate safety data in broader patient populations over a longer period of time, semi-implantable middle ear hearing aids are investigational for all indications. The impact on net health outcome cannot be determined.
The available evidence for use of fully implantable middle ear hearing aids is insufficient to demonstrate long-term improvement in net health outcome. Concerns exist about adverse events with these devices. Therefore, fully implantable middle ear hearing aids are considered investigational.
Practice Guidelines and Position Statements
No national guidelines on the use of semi- or fully-implantable hearing aids were identified on the National Guidelines Clearinghouse online at Guidelines.gov.
Medicare National Coverage
No national coverage determination has been published. The Medicare Benefit Policy Manual references hearing aids and auditory implants, stating that hearing aids are excluded from coverage.(28) However, devices which produce the perception of sound by replacing the function of the middle ear, cochlea, or auditory nerve are payable by Medicare as prosthetic devices. These devices are indicated only when hearing aids are medically inappropriate or cannot be utilized due to congenital malformations, chronic disease, severe sensorineural hearing loss or surgery. The benefit manual does not specifically refer to semi- or fully implantable hearing aids as prosthetic devices.
- Vibrant Soundbridge. FDA Summary of Safety and Effectiveness. Available online at: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cftopic/pma/pma.cfm?num=p990052. Last accessed March 8, 2012.
- Soundtec Direct System. FDA Summary of Safety and Effectiveness. Available online at: http://www.accessdata.fda.gov/cdrh_docs/pdf/P010023b.pdf. Last accessed March 8, 2012.
- Luetje CM, Brackman D, Balkany TJ et al. Phase III clinical trial results with the Vibrant Soundbridge implantable middle ear hearing device: a prospective controlled multicenter study. Otolaryngol Head Neck Surg 2002; 126(2):97-107.
- Sterkers O, Boucarra D, Labassi S et al. A middle ear implant, the Symphonix Vibrant Soundbridge: retrospective study of the first 125 patients implanted in France. Otol Neurotol 2003; 24(3):427-36.
- Tysome JR, Moorthy R, Lee A et al. Systematic review of middle ear implants: do they improve hearing as much as conventional hearing AIDS? Otol Neurotol 2010; 31(9):1369-75.
- Hough JV, Matthews P, Wood MW et al. Middle ear electromagnetic semi-implantable hearing device: results of the phase II SOUNDTEC direct system clinical trial. Otol Neurotol 2002; 23(6):895-903.
- Silverstein H, Atkins J, Thompson JH, Jr. et al. Experience with the SOUNDTEC implantable hearing aid. Otol Neurotol 2005; 26(2):211-7.
- Truy E, Philibert B, Vesson JF et al. Vibrant soundbridge versus conventional hearing aid in sensorineural high-frequency hearing loss: a prospective study. Otol Neurotol 2008; 29(5):684-7.
- Beltrame AM, Martini A, Prosser S et al. Coupling the Vibrant Soundbridge to cochlea round window: auditory results in patients with mixed hearing loss. Otol Neurotol 2009; 30(2):194-201.
- Gunduz B, Atas A, Bayazit YA et al. Functional outcomes of Vibrant Soundbridge applied on the middle ear windows in comparison with conventional hearing aids. Acta Otolaryngol 2012; 132(12):1306-10.
- Bernardeschi D, Hoffman C, Benchaa T et al. Functional results of Vibrant Soundbridge middle ear implants in conductive and mixed hearing losses. Audiol Neurootol 2011; 16(6):381-7.
- Sziklai I, Szilvassy J. Functional gain and speech understanding obtained by Vibrant Soundbridge or by open-fit hearing aid. Acta Otolaryngol 2011; 131(4):428-33.
- Colletti L, Carner M, Mandala M et al. The floating mass transducer for external auditory canal and middle ear malformations. Otol Neurotol 2011; 32(1):108-15.
- Mandala M, Colletti L, Colletti V. Treatment of the atretic ear with round window vibrant soundbridge implantation in infants and children: electrocochleography and audiologic outcomes. Otol Neurotol 2011; 32(8):1250-5.
- Roman S, Denoyelle F, Farinetti A et al. Middle ear implant in conductive and mixed congenital hearing loss in children. Int J Pediatr Otorhinolaryngol 2012; 76(12):1775-8.
- Venail F, Lavieille JP, Meller R et al. New perspectives for middle ear implants: first results in otosclerosis with mixed hearing loss. Laryngoscope 2007; 117(3):552-5.
- Zwartenkot JW, Mulder JJ, Snik AF et al. Vibrant Soundbridge surgery in patients with severe external otitis: complications of a transcanal approach. Otol Neurotol 2011; 32(3):398-402.
- Esteem Implantable Hearing System. FDA Summary of Safety and Effectiveness. Available online at: http://www.accessdata.fda.gov/cdrh_docs/pdf9/P090018b.pdf. Last accessed March 19, 2012.
- Kraus EM, Shohet JA, Catalano PJ. Envoy Esteem Totally Implantable Hearing System: phase 2 trial, 1-year hearing results. Otolaryngol Head Neck Surg 2011; 145(1):100-9.
- Barbara M, Biagini M, Monini S. The totally implantable middle ear device 'Esteem' for rehabilitation of severe sensorineural hearing loss. Acta Otolaryngol 2011; 131(4):399-404.
- Barbara M, Manni V, Monini S. Totally implantable middle ear device for rehabilitation of sensorineural hearing loss: preliminary experience with the Esteem, Envoy. Acta Otolaryngol 2009; 129(4):429-32.
- Chen DA, Backous DD, Arriaga MA et al. Phase 1 clinical trial results of the Envoy System: a totally implantable middle ear device for sensorineural hearing loss. Otolaryngol Head Neck Surg 2004; 131(6):904-16.
- Gerard JM, Thill MP, Chantrain G et al. Esteem 2 middle ear implant: our experience. Audiol Neurootol 2012; 17(4):267-74.
- Kam AC, Sung JK, Yu JK et al. Clinical evaluation of a fully implantable hearing device in six patients with mixed and sensorineural hearing loss: our experience. Clin Otolaryngol 2012; 37(3):240-4.
- Monini S, Biagini M, Atturo F et al. Esteem((R)) middle ear device versus conventional hearing aids for rehabilitation of bilateral sensorineural hearing loss. Eur Arch Otorhinolaryngol 2012 [Epub ahead of print].
- Tsang WS, Yu JK, Wong TK et al. Vibrant Soundbridge system: application of the stapes coupling technique. J Laryngol Otol 2013; 127(1):58-62.
- Klein K, Nardelli A, Stafinski T. A systematic review of the safety and effectiveness of fully implantable middle ear hearing devices: the carina and esteem systems. Otol Neurotol 2012; 33(6):916-21.
- Medicare Policy Benefit Manual. Chapter 16 - General Exclusions from Coverage. Available online at: http://www.cms.gov/manuals/Downloads/bp102c16.pdf. Last accessed March 8, 2012.
Unlisted procedure, middle ear
Implantation of magnetic component of semi-implantable hearing device on ossicles in middle ear
Semi-implantable middle ear hearing prosthesis
|ICD-10-CM (effective 10/1/14)||Investigational for all relevant diagnoses|
|H90.3||Sensorineural hearing loss, bilateral|
|H90.41-H90.42||Sensorineural hearing loss with unrestricted hearing on contralateral side code range|
|H90.5||Sensorineural hearing loss unspecified|
|ICD-10-PCS (effecitve 10/1/14)||ICD-10-PCS codes are only used for inpatient services. There is no specific ICD-10-PCS code for this procedure.|
|09HD0SY, 09HE0SY||Surgical, insertion, inner ear, open, hearing device, code by body part (right or left)|
Fully Implantable Hearing Aid
Hearing Aid, Fully Implantable
Hearing Aid, Semi-Implantable Middle Ear
Middle Ear Implant, Semi-Implantable
Semi-Implantable Middle Ear Hearing Aid for Moderate to Severe Sensorineural Hearing Loss
Add to Surgery section
Policy updated with literature search; no change in policy statement
Policy updated with literature search; no change in policy statement
Policy updated with literature search; no change in policy statement; reference number 6 added
|04/09/08||Replace policy||Policy updated with literature search; no change in policy statement; reference number 7 added|
|11/12/09||Replace policy||Policy updated with literature search February 2008 to September 2009; reference numbers 8 and 9 added; Policy statements are unchanged.|
|4/14/11||Replace policy||Policy updated with literature review, reference numbers 10-14 added, “fully implantable” hearing aid added to policy, title changed to reflect addition, fully implantable device considered investigational|
|04/12/12||Replace policy||Policy updated with literature review, rationale section reorganized, reference numbers 10-12, 14, 16 and 20 added, policy title changed with the removal of “for moderate to severe sensorineural hearing loss," policy statement unchanged|
|03/14/13||Replace policy||Policy updated with literature review through February 11, 2013; reference numbers 10, 12, 15, 23-27 added; policy statement unchanged|